GlassScriptPhysician profile
Jeffrey Herman
NPI 1043358286
$2,111.79
in general payments reported to CMS, 2019-2025
26 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $758 · 2024: $830 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089 · Education: $22.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.08 |
| Education | $22.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $355.58 | 2023-2025 | |
| Amgen INC. | $345.98 | 2024-2025 | Otezla, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $241.52 | 2023-2025 | Farxiga, Airsupra |
| Abbvie INC. | $239.70 | 2023-2025 | |
| Esperion Therapeutics, INC. | $90.52 | 2023-2025 | Nexletol |
| Novo Nordisk INC | $88.42 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.54 | 2024 | Jardiance |
| Lilly USA, LLC | $75.05 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $63.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $48.74 | 2023 | |
| Xeris Pharmaceuticals, INC. | $47.69 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $43.64 | 2025 | |
| Glaxosmithkline, LLC. | $43.27 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Seqirus USA INC | $41.91 | 2024-2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $38.98 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $36.13 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Axsome Therapeutics, INC. | $32.46 | 2025 | Auvelity |
| Inari Medical, INC. | $30.14 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.96 | 2025 | Relistor |
| Boston Scientific Corporation | $22.82 | 2025 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.80 | 2024 | Caplyta |
| Opko Pharmaceuticals, LLC | $22.71 | 2023 | Rayaldee |
| Abiomed | $19.27 | 2025 | |
| Sumitomo Pharma America, INC. | $19.22 | 2025 | Gemtesa |
| Halozyme INC | $19.06 | 2023 | |
| Sonex Health, INC. | $16.67 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.